News
CLVLF
6.10
NaN%
--
Clinuvel Files 20-F as It Pursues Nasdaq ADS Uplisting
TipRanks · 19h ago
Analysts Offer Insights on Healthcare Companies: Clinuvel Pharmaceuticals (OtherCLVLF) and Agios Pharma (AGIO)
TipRanks · 05/25 01:50
Clinuvel Issues 887,956 Unquoted Performance Rights Under Incentive Scheme
TipRanks · 05/07 01:57
Clinuvel advances Nasdaq Level II ADR plans amid ongoing SEC review
TipRanks · 04/27 23:46
FDA Drops QT Study Requirement for Clinuvel’s SCENESSE
TipRanks · 04/26 23:13
Clinuvel Pharmaceuticals (CLVLF) Gets a Buy from Jefferies
TipRanks · 04/26 12:18
Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE
TipRanks · 04/23 23:14
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
Barchart · 04/15 01:18
Clinuvel Issues New Shares, Confirms Compliance With Disclosure Rules
TipRanks · 04/12 23:21
Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile
TipRanks · 04/02 01:29
Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting
TipRanks · 03/26 22:03
Clinuvel Backs CEO Wolgen as Cash-Rich Biotech Prioritises Vitiligo Push
TipRanks · 03/19 22:04
Canaccord Genuity Keeps Their Buy Rating on Clinuvel Pharmaceuticals (CLVLF)
TipRanks · 03/02 16:55
Morgans Keeps Their Buy Rating on Clinuvel Pharmaceuticals (CLVLF)
TipRanks · 02/27 00:07
Bell Potter Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)
TipRanks · 02/26 22:36
Clinuvel Profit Dips on Higher Expansion Costs Despite Record Half-Year Revenue
TipRanks · 02/26 00:42
Clinuvel Flags Wide-Ranging Risks Ahead of Institutional Investor Meetings
TipRanks · 02/01 22:28
Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L
TipRanks · 01/11 22:37
Clinuvel Reports New Positive Vitiligo Data for SCENESSE® in Darker-Skinned Patients
TipRanks · 01/07 23:17
Clinuvel Pharmaceuticals Reports Lapse of 5,425 Performance Rights
TipRanks · 01/01 23:27
More
Webull provides a variety of real-time CLVLF stock news. You can receive the latest news about Clinuvel Pharma through multiple platforms. This information may help you make smarter investment decisions.
About CLVLF
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.